{"id":54065,"date":"2023-02-20T12:03:17","date_gmt":"2023-02-20T11:03:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/3d-cell-culture-technologies-global-market-report-2023-increasing-requirement-for-organ-transplantation-drives-sector-researchandmarkets-com\/"},"modified":"2023-02-20T12:03:17","modified_gmt":"2023-02-20T11:03:17","slug":"3d-cell-culture-technologies-global-market-report-2023-increasing-requirement-for-organ-transplantation-drives-sector-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/3d-cell-culture-technologies-global-market-report-2023-increasing-requirement-for-organ-transplantation-drives-sector-researchandmarkets-com\/","title":{"rendered":"3D Cell Culture Technologies Global Market Report 2023: Increasing Requirement for Organ Transplantation Drives Sector – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “3D Cell Culture Technologies Global Market Report 2023”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global 3D cell culture technologies market is expected to grow from $2.03 billion in 2021 to $2.39 billion in 2022 at a compound annual growth rate (CAGR) of 18.0%. The 3D cell culture technologies market is expected to reach $4.71 billion in 2026 at a CAGR of 18.5%.\n<\/p>\n

\nNorth America was the largest region in the 3D cell culture technologies market in 2022. Western Europe was the second largest region in the 3D cell culture technologies market. The regions covered in the 3D cell culture technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.\n<\/p>\n

\nThe increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening.\n<\/p>\n

\nFor instance, according to the Organ Procurement and Transplantation network, an American non-profit organization administering the organ transplantation in the US, 41,354 organ transplantations were performed in the United States in 2021 which was an increase of 5.9% as compared to 2020 and the number exceeded 40,000 mark for the first time ever. .\n<\/p>\n

\nThe possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff’s university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures.\n<\/p>\n

\nImplementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement in the market for 3D cell culture, this is the use of the vivo\/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek’s 3D cell expansion system to be used as a medical device. It also approved Biotek’s Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA-approved implants and drug delivery devices.\n<\/p>\n

\nFDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include consistent documentation of the receipts.\n<\/p>\n

\nIn May 2021, CELLINK Group, a USA-based start-up that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology.\n<\/p>\n

\nReasons to Purchase<\/strong>\n<\/p>\n